Early-stage breast cancer and surgical-adjuvant care
Research activity includes early breast cancer, invasive breast cancer in early stages, and patients with node-positive disease requiring decisions about adjuvant treatment. The sponsor also works in neoadjuvant therapy for intermediate- and high-risk disease, with attention to treatment selection before surgery and subsequent adjuvant endocrine therapy.
- Hormone receptor-positive early-stage disease
- Node-positive breast cancer
- Recurrence Score-guided treatment decisions
Clinical interest extends to long-term follow-up after early-stage treatment, including patterns of first relapse and outcomes after neoadjuvant and adjuvant care.
HER2-positive and HER2-negative advanced disease
The sponsor studies HER2-positive breast cancer across locally advanced and metastatic settings, including non-resectable disease and tumors resistant to prior anti-HER2 therapy. It also supports research in metastatic breast cancer with distinct biologic subtypes, including HR-positive/HER2-negative disease.
- Locally advanced breast cancer
- Metastatic breast cancer
- Anti-HER2 treatment-resistant disease
Its portfolio reflects sustained interest in treatment strategies for advanced disease with different receptor profiles and prior endocrine or targeted therapy exposure.
Targeted therapy and molecularly defined subgroups
Key areas include PIK3CA-mutated breast cancer, HER2-positive disease with HR-positive or hormone receptor-negative features, and patients previously treated with trastuzumab-based regimens. The sponsor is active in research on targeted combinations involving PI3K inhibition, CDK4/6 inhibition, and additional anti-HER2 agents.
- PIK3CA-mutated advanced breast cancer
- CDK4/6 inhibitor-based treatment
- Dual and triple anti-HER2 strategies
These studies focus on biologically selected populations in whom receptor status and molecular alterations guide therapeutic interest.
Endocrine therapy and quality of life
Another area of interest is hormone-driven breast cancer, particularly in postmenopausal women with metastatic disease and in patients receiving long-term endocrine treatment. The sponsor also supports work on symptom burden, treatment persistence, and quality of life during endocrine-based care.
- Fulvestrant-based treatment
- Aromatase inhibitor therapy
- Endocrine therapy adherence and tolerability
Research topics include the impact of physical activity and supportive interventions on treatment-related well-being in patients with breast cancer.
Treatment tolerability and supportive care
The sponsor funds studies addressing adverse effects and treatment continuation, with particular attention to diarrhoea related to anti-HER2 therapy and tolerability of extended oral treatment. Supportive care also includes monitoring patient-reported outcomes during prolonged systemic therapy.
- Anti-diarrhoeal management
- Therapy discontinuation due to adverse events
- Patient-reported quality of life
These interests complement its broader breast cancer portfolio by addressing the practical impact of treatment on daily functioning and continuation of care.
